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Introduction
Th  e partial pressure of CO2 in the blood (PaCO2) 
represents the balance between CO2 produced, CO2
eliminated, and CO2 (rarely) inspired:
CO2 production
PaCO2  ___________________________  + inspired [CO2]
CO2 elimination
For practical purposes, PaCO2 reﬂ  ects the rate of CO2 
elimina tion.
Prevalence and causes of altered CO2 tension
Th  ere are no common physiological causes of hyper-
capnia. Historically, uses of CO2 included elimination of 
carbon monoxide poisoning, augmentation of cerebral 
perfusion during carotid endarterectomy, hastening 
emergence from general anesthesia, and as treatment for 
retinal artery occlusion.
Th  e commonest reason for hypercapnia in ventilated 
patients is a reduced tidal volume (VT); this situation is 
termed permissive hypercapnia. Accidental hypercapnia 
occurs with problems such as circuit misconnections that 
permit rebreathing. Increased CO2 production is un-
common, but occurs with hyperpyrexia, shivering, 
neuro  leptic malignant syndrome, heat stroke, thyro-
toxicosis or pheochromocytoma.
Indirect calorimetry utilizes whole-body CO2
production, together with O2 consumption, to reﬂ  ect the 
amount of energy released from substrate oxidation (that 
is, the oxidation of carbohydrates, lipids and proteins), 
although it is more accurate at assessing resting energy 
expenditure. As such, massive carbohydrate oxygenation 
may contribute to hypercapnia in patients with impaired 
pulmonary diﬀ  usion [1].
Hypocapnia may be physiologic, accidental, or induced 
(Table  1). In the critically ill patient, hypocapnia can 
develop with excessive mechanical ventilation or with 
cardiopulmonary bypass, high-frequency ventilation, or 
extracorporeal membrane oxygenation. It may be 
deliberately induced when intracranial pressure [2] – or 
neonatal pulmonary artery pressure [3] – is elevated.
Importance of altered CO2 tension in critical illness
Hypercapnia
High VT causes, or potentiates, lung injury [4]. Smaller 
VT often leads to elevated PaCO2, termed permissive 
hypercapnia, and is associated with better survival [5,6]. 
Th  ese  low-VT strategies are not conﬁ  ned to patients with 
acute lung injury (ALI)/acute respiratory distress syn-
drome (ARDS); they were ﬁ   rst reported successful in 
severe asthma [7], and attest to the overall safety of 
hypercapnia. Indeed, hyper  capnia in the presence of 
higher VT may independently improve survival [8].
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Hypocapnia is common in several diseases (Table 1; for 
example, early asthma, high-altitude pulmonary edema, 
lung injury), is a common acid–base disturbance and a 
criterion for systemic inﬂ  ammatory response syndrome 
[9], and is a prognostic marker of adverse outcome in 
diabetic ketoacidosis [10]. Hypocapnia – often prolonged – 
remains common in the management of adult [11] and 
pediatric [12] acute brain injury.
Carbon dioxide transport, sensing and molecular 
response
CO2 is carried in the blood as HCO3
–, in combination 
with hemoglobin and plasma proteins, and in solution. 
Inside the cell, CO2 interacts with H2O to produce 
carbonic acid (H2CO3), which is in equilibrium with H+ 
and HCO3
–, a reaction catalyzed by carbonic anhydrase. 
CO2 transport into cells is complex, and passive diﬀ  usion, 
speciﬁ   c transporters and rhesus proteins may all be 
involved.
CO2 is sensed in central and peripheral neurons. 
Changes in CO2 and H+ are sensed in chemosensitive 
neurons in the carotid body and in the hindbrain [13,14]. 
Whether CO2 or the pH are preferentially sensed is 
unclear, but the ventilatory response to hypercapnic 
acidosis (HCA) exceeds that of an equivalent degree of 
metabolic acidosis [15], suggesting speciﬁ  c CO2 sensing. 
Bicarbonate directly activates adenylate cyclase [16], 
increasing cAMP and activating protein kinase A, 
opening Ca2+ channels and permitting inﬂ  ux of Ca2+ [14]. 
In the glomus cells of the carotid nucleus, increased CO2 
levels activate Ca2+ channels independent of the pH [17].
A key molecular mechanism by which hypercapnia 
may exert its eﬀ  ects, both beneﬁ  cial and deleterious, is 
through the NF-κB transcription factor. NF-κB is a major 
transcription factor that regulates genes responsible for 
immunity and inﬂ  ammation, including proinﬂ  ammatory 
cytokines. An in vitro study has demonstrated that 
elevated CO2 levels suppress expression of TNF and 
other cytokines by pulmonary artery endothelial cells via 
suppression of NF-κB activation [18]. Furthermore, 
hyper  capnia inhibits pulmonary epithelial wound repair, 
also via an NF-κB mechanism [19].
Physiologic eff  ects of CO2
Th  e physiologic eﬀ   ects of CO2 are diverse and in-
completely understood, with direct eﬀ  ects often counter-
balanced by indirect eﬀ  ects. In addition, the net eﬀ  ect of 
hypocapnia or hypercapnia may occur as a function of 
the pH or CO2 per se.
Respiratory system
CO2 is important in matching regional lung ventilation to 
perfusion. Alveolar CO2 increases local alveolar ventila-
tion [20] via inhibition of conducting airway tone. 
Hypercapnia increases pulmonary vascular tone, poten-
tiating hypoxic pulmonary vasoconstriction and further 
augment  ing V/Q matching, but in some cases exacer-
bating pulmonary hypertension.
Hypocapnia can worsen ventilation–perfusion match  ing 
and gas exchange in the lung via a number of mechanisms, 
including bronchoconstriction [21], reduc  tion in collateral 
ventilation [22], reduction in paren  chymal compliance 
[23], and attenuation of hypoxic pulmonary vaso  con-
striction and increased intra  pulmo  nary shunting [24].
Central nervous system
CO2 stimulates ventilation (see above). Peripheral chemo-
receptors respond more rapidly than the central neurons, 
but central chemosensors make a larger contribution to 
stimulating ventilation. CO2 increases cerebral blood 
ﬂ  ow (CBF) by 1 to 2 ml/100 g/minute per 1 mmHg in 
PaCO2 [25], an eﬀ  ect mediated by pH rather than by the 
partial pressure of CO2. Hypercapnia elevates both the 
partial pressure of O2 in the blood and CBF, and reducing 
PaCO2 to 20 to 25 mmHg decreases CBF by 40 to 50% 
[26]. Th  e  eﬀ  ect of CO2 on CBF is far larger than its eﬀ  ect 
on the cerebral blood volume. During sustained 
hypocapnia, CBF recovers to within 10% baseline by 4 
hours; and because lowered HCO3
– returns the pH 
towards normal, abrupt normalization of CO2 results in 
(net) alkalemia and risks rebound hyperemia.
Hypocapnia increases both neuronal excitability and 
excitatory (glutamatergic) synaptic transmission, and 
suppresses GABA-A-mediated inhibition, resulting in 
increased O2 consumption and uncoupling of metabolism 
to CBF [27].
Table 1. Causes of hypocapnia
Hypoxemia  Altitude, pulmonary disease
Pulmonary disorders  Pneumonia, interstitial pneumonitis, fi  brosis, edema, pulmonary emboli, vascular disease, bronchial asthma, pneumothorax
Cardiovascular system disorders  Congestive heart failure, hypotension
Metabolic disorders  Acidosis (diabetic, renal, lactic), hepatic failure
Central nervous system disorders  Psychogenic/anxiety hyperventilation, central nervous system infection, central nervous system tumors
Drug induced  Salicylates, methylxanthines, β-adrenergic agonists, progesterone
Miscellaneous  Fever, sepsis, pain, pregnancy
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Hypercapnia directly inhibits cardiac and vascular 
muscle contractility, eﬀ  ects that are counterbalanced by 
sympathoadrenal increases in heart rate and contractility, 
increasing the cardiac output overall [28]. Th  e partial 
pressure of O2 in the blood is increased because increased 
cardiac output coupled with reduced intra  pulmonary 
shunt increases O2 delivery, and tissue release of O2 is 
augmented because hypercapnia and acidemia shift the 
hemoglobin–O2 curve rightward. In addition, HCA 
increases the O2 tension in both subcutaneous tissues 
and in the intestinal wall [29].
Indeed, a large body of evidence now attests to the 
ability of hypercapnia to increase peripheral tissue 
oxygenation, independently of its eﬀ   ects on cardiac 
output [30,31]. In experimental polymicrobial sepsis in 
female sheep, HCA improved tissue oxygenation and 
reduced lung edema formation more than dobutamine 
administration [32]. A study in white rabbits ascertained 
that 150 mmHg was the permissive upper limit of acute 
hypercapnia with respect to improvement of tissue 
perfusion and oxygenation [33]. Finally, a further positive 
eﬀ  ect of HCA on bioenergetics is evident in the form of a 
reduction in cellular O2 consumption [34] and hyper-
capnia induced mitigation of the fall in gut ATP during 
endotoxemia in rats, pointing to improvement in energy 
metabolism in this setting. Th  e net impact is thus 
increased O2 supply and less demand. In contrast, hypo-
capnia does the opposite.
Carbon dioxide – insights from the bench
Experimental studies provide important preclinical 
information on the eﬀ  ects and mechanisms of action of 
CO2.
Acute lung injury
HCA is protective in many models of ALI. Although 
hypercapnia reduces the severity of overwhelming 
experimental ventilator-induced lung injury [35], its 
eﬀ  ects in milder injury are modest [36] and it may not 
protect in extensive atelectasis [37]. Hypercapnia inhibits 
hypoxia-induced chronic pulmonary hypertension in 
adult and newborn rodents [38,39], and protects against 
chronic neonatal lung injury [40]. Th  e beneﬁ  cial eﬀ  ects 
of HCA in such models are increasingly well understood, 
and include attenuation of lung neutrophil recruitment, 
pulmonary and systemic cytokine concentrations, cell 
apoptosis, and O2-derived and nitrogen-derived free 
radical injury.
Concern has been raised regarding the potential for the 
anti-inﬂ  ammatory  eﬀ   ects of HCA to impair the host 
response to infection. In early pulmonary infection, this 
potential impairment does not appear to occur, with 
HCA reducing the severity of acute-severe Escherichia 
coli pneumonia-induced ALI [41]. In the setting of more 
established  E.  coli pneumonia, HCA is also protective 
[42]. Of concern, HCA worsens the severity of prolonged 
bacterial pneu  monia by a mechanism involving reduced 
bacterial killing [43]. In contrast, HCA reduces the 
severity of lung injury and hemodynamic compromise 
caused by cecal ligation and puncture-induced 
polymicrobial systemic sepsis [44,45]. Th  e  eﬀ  ects of HCA 
in sepsis therefore appear to depend on the duration of 
infection and on the site of infection. Other potential 
adverse eﬀ  ects of hypercapnia may include impairment 
of alveolar epithelial function, leading to reduced edema 
clearance [46]. Lastly, HCA may delay cellular repair and 
wound healing [19], slowing recovery and healing 
following ALI/ARDS.
Hypocapnia increases microvascular permeability and 
impairs alveolar ﬂ   uid reabsorption in the isolated rat 
lung, due to an associated decrease in Na/K-ATPase 
activity [47]. Th  ese  eﬀ  ects may be important in the patho-
genesis of pulmonary edema. Experimental hypocapnia 
causes profound acute parenchymal lung injury that may 
be ameliorated by normalization of alveolar CO2 by add-
ing inspired CO2 [48]; it also worsens ischemia–
reperfusion-induced lung injury [49].
Myocardial and vascular injury
HCA protects the heart following ischemia–reperfusion 
injury. Reperfusion with a hypercapnia acidotic perfusate 
enhances recovery of myocardial function following 
prolonged ischemia ex vivo as well as in vivo [50]. In 
experimental polymicrobial sepsis in female sheep, HCA 
improved tissue oxygenation and reduced lung edema 
formation more than dobutamine administration [32]. 
Hypocapnia worsens ischemic injury in the neonatal 
lamb myocardium [51] and abolishes the protective 
eﬀ  ects of preconditioning.
Central nervous system
Hypercapnia attenuates hypoxic-ischemic brain injury in 
the immature rat [52] and protects the porcine brain 
from reoxygenation injury by attenuation of free radical 
action. Hypercapnia increases the size of the region at 
risk of infarction in experimental acute focal ischemia; in 
hypoxic-ischemic injury in the immature rat brain, 
hypocapnia worsens the histologic magnitude of stroke 
[52] and is associated with a decrease in CBF to the 
hypoxia-injured brain as well as disturbance of glucose 
utilization and phosphate reserves. Hypocapnia during 
resuscitation increases functional and histologic evidence 
of brain injury following experimental cardiac arrest in 
dogs [53]. Hypocapnia further exacerbates the cerebral 
O2 supply:demand imbalance by increasing neuronal 
excitability, increasing excitatory synaptic transmission, 
and via a direct eﬀ  ect on the neuronal membrane itself 
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acid receptor-mediated neurotoxicity in the newborn 
piglet and increases neuronal dopamine, particularly in 
the striatum, which may worsen reperfusion injury, 
especially in the immature brain [55]. Indeed, hypocapnia 
may be directly neurotoxic, through increased incor-
poration of choline into membrane phospholipids [56].
Clinical profi  le of hypocapnia in the critically ill 
patient
Potential benefi  ts
Th  ere are some potential beneﬁ  ts of acute hypocapnic 
alkalosis in speciﬁ  c critically ill patients [57]. For patients 
who have life-threatening elevations in intracranial 
pressure, rapid induction of hypocapnia for short dura-
tions may prevent brainstem herniation, allowing 
deﬁ  nitive diagnosis and therapy to be instituted. Hypo-
capnia may also be indicated in neonates with pulmonary 
hypertensive crises. Th  e knowledge of the dramatic 
deleterious eﬀ  ects of hypocapnia on the neonatal brain, 
together with the known adverse eﬀ  ects of excessive lung 
stretch, however, have led to the use of alternative 
measures in this regard. Th  ere are very few other 
situations where hypocapnia is of beneﬁ  t.
Potential risks
Hypocapnia may be a pathogenic entity in the setting of 
critical illness, particularly in ARDS patients. Edmunds 
and Holm demonstrated more than 30 years ago that 
alveolar hypocapnia produces hemorrhagic consolidation 
in the lung, and that attenuation of such adverse eﬀ  ects 
could be achieved by addition of inhaled CO2 [48]. In the 
clinical context, Trimble and colleagues in 1971 demon-
strated that hypocapnia increased airway resistance, 
increased work of breathing, worsened ventilation/
perfusion matching, increased the alveolar–arterial O2 
gradient and decreased the partial pressure of O2 in the 
blood in ARDS patients, and that administration of CO2 
(that is, therapeutic hypercapnia) improved systemic 
oxygenation and reduced the shunt fraction [58]. Both 
hyperventilation and hypocapnia have been identiﬁ  ed as 
independent determinants of long-term pulmonary dys-
function in patients with bronchopulmonary dysplasia, 
as well as being implicated in the pathogenesis of asthma.
In traumatic brain injury, sustained hypocapnia may 
exacerbate cerebral hypoperfusion. Hypocapnia-induced 
cerebral vasoconstriction may worsen cerebral vaso-
spasm in these patients, and has been demonstrated to 
exacerbate pre-existing impairment of CBF and meta-
bolism in patients with traumatic brain injury. Coles and 
colleagues demonstrated that moderate hypocapnia 
(<34  mmHg) can signiﬁ   cantly reduce global CBF and 
result in signiﬁ  cant increases in the volume of critically 
hypoperfused tissue in the injured brain [27]. 
Prophylactic hyperventilation of head-injured patients, 
formerly employed in order to reduce intracranial 
pressure, worsens outcome [59]. In children with severe 
head injury, hypocapnia-induced critical cerebral ischemia 
has also been demonstrated. In the setting of resusci-
tation following cardiac arrest, hypocapnia induces 
cerebral ischemia in the post-resuscitation period [60]. 
Hypocapnic aklalosis has also been associated with poor 
prognosis in patients with acute cerebrovascular 
accidents.
In the critically ill patient, hypocapnia has been clearly 
linked to the development of arrhythmias, adversely 
aﬀ   ects the myocardial supply:demand balance [61], 
increases the risk of coronary vasospasm [62], and may 
worsen the progression of acute coronary syndromes.
Clinical profi  le of hypercapnia in the critically ill 
patient
Potential benefi  ts
Th   ere are no clinical studies of hypercapnia independent 
of VT in mechanical ventilation strategies. Indirect 
evidence exists in humans, however, for a protective 
eﬀ   ect of HCA independent of VT. Kregenow and 
colleagues examined mortality as a function of permissive 
hypercapnia in patients enrolled in the ARDS Network 
VT study [4,8]. Using multivariate logistic regression 
analysis, and controlling for other co-morbidities and 
severity of lung injury, they demonstrated that permissive 
hypercapnia reduced mortality in patients randomized to 
the higher VT (12 ml/kg) [8]. Th  ere was, however, no 
additional protective eﬀ  ect of permissive hypercapnia in 
patients randomized to receive the lower VT (6 ml/kg) [8].
In children with congenital heart disease undergoing 
cardiopulmonary bypass, blood gas management with a 
pH-stat strategy, which results in higher PaCO2 levels, 
reduces postoperative morbidity [63].
Potential risks
Rapid induction of hypercapnia in the critically ill patient 
may have adverse eﬀ   ects. Acute hypercapnia impairs 
myocardial function. HCA may induce vasoconstriction 
of the pulmonary vascular bed, leading to right 
ventricular systolic overload; and in patients with ARDS, 
HCA may exacerbate hypoxic vasoconstriction. In 
patients with severe ARDS, HCA – induced by VT 
reduction and increases in positive end-expiratory 
pressure – impaired right ventricular function and 
hemodynamics despite positive eﬀ  ects on oxygenation 
and alveolar recruitment [64]. An adverse eﬀ  ect  of 
hypercapnia on skeletal muscle function, and 
diaphragmatic function in particular, is a concern.
Hypercapnia-induced increases in CBF and cerebral 
blood volume may adversely impact on intracranial 
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association between intraventricular hemorrhage and 
severe, but not mild, hypercapnia has been reported in 
retrospective studies.
Deﬁ  ning a safe and eﬃ   cacious threshold of hypercapnia 
remains an elusive goal. Although beneﬁ  cial  eﬀ  ects, 
including tissue oxygenation, may have a ceiling level in 
animals [33], similar ﬁ  ndings have not been reported in 
humans. Evidence of a temporal limit to beneﬁ  cial eﬀ  ects 
undermines this concept further – timing (that is, 
adaptation) may be as important as the degree of severity. 
Attempts to specify such a value are problematic outside 
the clinical context. Clinicians must be mindful of the 
tradeoﬀ   between the beneﬁ  cial and deleterious eﬀ  ects of 
hypercapnia as outlined, and must tailor treatment in 
each individual case; for example, in the case of combined 
lung and head injury, regional monitors of cerebral 
oxygenation and intracranial pressure may be used to 
guide therapy.
Therapeutic hypercapnia in the critically ill patient
Despite extensive eﬀ  ort over the past decade, particularly 
in the experimental setting, the ideal target population 
for trials of therapeutic hypercapnia (that is, 
administration of CO2 to the ventilator breathing circuit) 
remains somewhat ill-deﬁ   ned. Given the immuno-
suppressive eﬀ  ects of HCA, and its potential to retard 
reparative processes, HCA may ultimately prove its 
utility as a temporary and brief measure, designed to 
limit predictable and transient organ injury. In that 
respect, therapeutic hypercapnia during or immediately 
post cardiopulmonary bypass would appear to hold some 
promise. HCA is protective in numerous experimental 
models of organ ischemia–reperfusion, and recent clinical 
studies have shown improved systemic oxygenation with 
the use of thera  peutic hypercapnia after bidirectional 
superior cavo  pulmonary anastomosis in children [65].
Hypercapnia in the critically ill patient – role of 
buff  ering
In patients managed with protective ventilation strate-
gies, buﬀ  ering of the acidosis induced by hypercapnia 
remains a common – albeit controversial – clinical 
practice. Buﬀ   ering with sodium bicarbonate was 
permitted in the ARDS Network VT study [4]. Th  e  need 
to consider the eﬀ  ects of buﬀ  ering HCA is emphasized 
by the fact that both hypercapnia and acidosis per se may 
exert distinct biologic eﬀ  ects. Th  ere is no evidence to 
support buﬀ   ering, however, and a number of speciﬁ  c 
concerns exist regarding this practice. Th  e protective 
eﬀ  ects of HCA in experimental lung injury are a function 
of the acidosis, rather than the elevated CO2 per se [66], 
and therefore buﬀ  ering may simply ablate any protective 
eﬀ  ects. In experimental lung injury induced by E. coli or 
endotoxin, renal buﬀ   ering of hypercapnia signiﬁ  cantly 
worsened physiological and histological measurements 
of injury [67].
Speciﬁ  c concerns exist regarding sodium bicarbonate, 
the buﬀ  er used most frequently in the clinical setting. 
Th  e eﬀ  ectiveness of bicarbonate infusion as a buﬀ  er is 
dependent on the ability to excrete CO2, rendering it less 
eﬀ   ective in buﬀ   ering HCA. In fact, bicarbonate may 
further raise PaCO2 where alveolar ventilation is limited, 
such as in ARDS. While bicarbonate may correct the 
arterial pH, it may worsen an intracellular acidosis 
because the CO2 produced when bicarbonate reacts with 
metabolic acids diﬀ  uses readily across cell membranes, 
whereas bicarbonate cannot.
Th   ere may be a role for alternative buﬀ  ers, such as the 
amino alcohol tromethamine (tris-hydroxymethyl amino-
methane (THAM)). THAM penetrates cells easily and 
can buﬀ  er pH changes and simultaneously reduce the 
partial pressure of CO2 [68]. Unlike bicarbonate, which 
requires an open system for CO2 elimination in order to 
exert its buﬀ  ering eﬀ  ect, THAM is eﬀ  ective in a closed or 
semi-closed system [68]. THAM rapidly restores pH and 
acid–base regulation in acidemia caused by CO2 
retention [68]. In ARDS patients, THAM attenu  ates the 
hemodynamic consequences of a rapidly induced HCA.
In summary, if a clinician elects to buﬀ  er HCA, the 
rationale for this practice should be clear – for example, 
to ameliorate potentially deleterious hemodynamic 
conse  quences of acidosis – and THAM should be 
considered rather than bicarbonate.
Summary and conclusions
Th  e importance and complexity of inter-relationships 
between alterations in systemic CO2 tension and critical 
illness states is increasingly appreciated. Ventilator 
strategies involving hypercapnia are widely utilized in the 
critically ill adult and child, with the aim of realizing the 
beneﬁ   ts of reduced lung stretch. Th  e potential for 
hypercapnia to directly contribute to the beneﬁ  cial 
eﬀ  ects of protective lung ventilatory strategies is clear 
from experimental studies demonstrating protective 
eﬀ  ects in models of acute lung and systemic organ injury. 
Concerns persist, however, regarding the potential for 
hypercapnia and/or acidosis to exert deleterious eﬀ  ects, 
and the need for caution prior to extrapolation to the 
clinical context must be emphasized.
Hypocapnia is an underappreciated phenomenon in 
the critically ill patient, and is potentially deleterious, 
particularly when severe or prolonged. Hypocapnia 
should be avoided except in speciﬁ  c clinical situations; 
when induced, hypercapnic acidosis should be for speciﬁ  c 
indications while deﬁ  nitive measures are undertaken.
A clearer understanding of the eﬀ  ects and mechanisms 
of action of CO2 is central to determining its safety and 
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coming years, research eﬀ   orts should focus on deter-
mining the potential mechanisms by which alterations in 
CO2 tension contribute to the pathogenesis of acute 
organ injury states. Such insights should advance our 
understanding of the situations in which hypercapnia or 
hypocapnia may be helpful or dangerous, and should 
guide clinicians with regard to the rational use of CO2 in 
the critically ill patient.
Abbreviations
ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CBF, cerebral 
blood fl  ow; CO2, carbon dioxide; HCA, hypercapnic acidosis; NF, nuclear factor; 
O2, oxygen; PaCO2, partial pressure of carbon dioxide in the blood; THAM, tris-
hydroxymethyl aminomethane; TNF, tumor necrosis factor; VT, tidal volume. 
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
This manuscript was supported in part by a fellowship from Molecular 
Medicine Ireland (to GC), and funding from the European Research Council 
(to JGL) under the Framework 7 program. BPK holds the Dr Geoff  rey Barker 
Chair in Critical Care Medicine, and is supported by the Canadian Institutes for 
Health Research
Author details
1Department of Anaesthesia, Clinical Sciences Institute, National University of 
Ireland, Galway, Ireland. 2Lung Biology Group, National Centre of Biomedical 
Engineering Sciences, National University of Ireland, Galway, Ireland. 
3Departments of Critical Care Medicine and Anesthesia and the Program 
in Physiology and Experimental Medicine, The Hospital for Sick Children, 
University of Toronto, 555 university Avenue, Toronto, ON M5G 1X8, Canada.
Published: 30 April 2010
References
1.  Radrizzani D, Iapichino G: Nutrition and lung function in the critically ill 
patient. Clin Nutr 1998, 17:7-10.
2.  Marion DW, Spiegel TP: Changes in the management of severe traumatic 
brain injury: 1991–1997. Crit Care Med 2000, 28:16-18.
3.  Drummond WH, Gegory GA, Heymann MA, Phibbs RA: The independent 
eff  ects of hyperventilation, tolazoline, and dopamine on infants with 
persistent pulmonary hypertension. J Pediatr 1981, 98:603-611.
4.  Ventilation with lower tidal volumes as compared with traditional tidal 
volumes for acute lung injury and the acute respiratory distress syndrome. 
The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000, 
342:1301-1308.
5.  Hickling KG, Walsh J, Henderson S, Jackson R: Low mortality rate in adult 
respiratory distress syndrome using low-volume, pressure-limited 
ventilation with permissive hypercapnia: a prospective study. Crit Care Med 
1994, 22:1568-1578.
6.  Wung JT, James LS, Kilchevsky E, James E: Management of infants with 
severe respiratory failure and persistence of the fetal circulation, without 
hyperventilation. Pediatrics 1985, 76:488-494.
7.  Darioli R, Perret C: Mechanical controlled hypoventilation in status 
asthmaticus. Am Rev Respir Dis 1984, 129:385-387.
8.  Kregenow DA, Rubenfeld GD, Hudson LD, Swenson ER: Hypercapnic acidosis 
and mortality in acute lung injury. Crit Care Med 2006, 34:1-7.
9.  Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, 
Sibbald WJ: Defi  nitions for sepsis and organ failure and guidelines for the 
use of innovative therapies in sepsis. Chest 1992, 101:1644-1655.
10.  Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, Louie J, Kaufman F, Quayle 
K, Roback M, Malley R, Kuppermann N: Risk factors for cerebral edema in 
children with diabetic ketoacidosis. The Pediatric Emergency Medicine 
Collaborative Research Committee of the American Academy of 
Pediatrics. N Engl J Med 2001, 344:264-269.
11.  Neumann JO, Chambers IR, Citerio G, Enblad P, Gregson BA, Howells T, 
Mattern J, Nilsson P, Piper I, Ragauskas A, Sahuquillo J, Yau YH, Kiening K: 
The use of hyperventilation therapy after traumatic brain injury in Europe: 
an analysis of the BrainIT database. Intensive Care Med 2008, 34:1676-1682.
12.  Curry R, Hollingworth W, Ellenbogen RG, Vavilala MS: Incidence of hypo- and 
hypercarbia in severe traumatic brain injury before and after 2003 
pediatric guidelines. Pediatr Crit Care Med 2008, 9:141-146.
13.  Forster HV, Martino P, Hodges M, Krause K, Bonis J, Davis S, Pan L: The carotid 
chemoreceptors are a major determinant of ventilatory CO2 sensitivity 
and of PaCO2 during eupneic breathing. Adv Exp Med Biol 2008, 
605:322-326.
14.  Putnam RW, Filosa JA, Ritucci NA: Cellular mechanisms involved in CO2 and 
acid signaling in chemosensitive neurons. Am J Physiol Cell Physiol 2004, 
287:C1493-C1526.
15.  Borison HL, Hurst JH, McCarthy LE, Rosenstein R: Arterial hydrogen ion 
versus CO2 on depth and rate of breathing in decerebrate cats. Respir 
Physiol 1977, 30:311-325.
16.  Chen Y, Cann MJ, Litvin TN, Iourgenko V, Sinclair ML, Levin LR, Buck J: Soluble 
adenylyl cyclase as an evolutionarily conserved bicarbonate sensor. 
Science 2000, 289:625-628.
17.  Summers BA, Overholt JL, Prabhakar NR: CO2 and pH independently 
modulate L-type Ca2+ current in rabbit carotid body glomus cells. 
J Neurophysiol 2002, 88:604-612.
18.  Takeshita K, Suzuki Y, Nishio K, Takeuchi O, Toda K, Kudo H, Miyao N, Ishii M, 
Sato N, Naoki K, Aoki T, Suzuki K, Hiraoka R, Yamaguchi K: Hypercapnic 
acidosis attenuates endotoxin-induced nuclear factor-κB activation. Am J 
Respir Cell Mol Biol 2003, 29:124-132.
19.  O’Toole D, Hassett P, Contreras M, Higgins BD, McKeown ST, McAuley DF, 
O’Brien T, Laff  ey JG: Hypercapnic acidosis attenuates pulmonary epithelial 
wound repair by an NF-κB dependent mechanism. Thorax 2009, 
64:976-982.
20.  Domino KB, Emery MJ, Swenson ER, Hlastala MP: Ventilation heterogeneity 
is increased in hypocapnic dogs but not pigs. Respir Physiol 1998, 
111:89-100.
21.  Rodarte JR, Hyatt RE: Eff  ect of acute exposure to CO2 on lung mechanics in 
normal man. Respir Physiol 1973, 17:135-145.
22.  Traystman RJ, Terry PB, Menkes HA: Carbon dioxide – a major determinant 
of collateral ventilation. J Appl Physiol 1978, 45:69-74.
23.  Emery MJ, Eveland RL, Kim SS, Hildebrandt J, Swenson ER: CO2 relaxes 
parenchyma in the liquid-fi  lled rat lung. J Appl Physiol 2007, 103:710-716.
24.  Domino KB, Swenson ER, Polissar NL, Lu Y, Eisenstein BL, Hlastala MP: Eff  ect of 
inspired CO2 on ventilation and perfusion heterogeneity in 
hyperventilated dogs. J Appl Physiol 1993, 75:1306-1314.
25.  Grubb RL, Jr, Raichle ME, Eichling JO, Ter-Pogossian MM: The eff  ects of 
changes in PaCO2 on cerebral blood volume, blood fl  ow, and vascular 
mean transit time. Stroke 1974, 5:630-639.
26.  Alexander SC, Smith TC, Strobel G, Stephen GW, Wollman H: Cerebral 
carbohydrate metabolism of man during respiratory and etabolic 
alkalosis. J Appl Physiol 1968, 24:66-72.
27.  Coles JP, Fryer TD, Coleman MR, Smielewski P, Gupta AK, Minhas PS, Aigbirhio 
F, Chatfi  eld DA, Williams GB, Boniface S, Carpenter TA, Clark JC, Pickard JD, 
Menon DK: Hyperventilation following head injury: eff  ect on ischemic 
burden and cerebral oxidative metabolism. Crit Care Med 2007, 35:568-578.
28.  Cullen DJ, Eger EI, 2nd: Cardiovascular eff  ects of carbon dioxide in man. 
Anesthesiology 1974, 41:345-349.
29.  Ratnaraj J, Kabon B, Talcott MR, Sessler DI, Kurz A: Supplemental oxygen and 
carbon dioxide each increase subcutaneous and intestinal intramural 
oxygenation. Anesth Analg 2004, 99:207-211.
30.  Akca O, Doufas AG, Morioka N, Iscoe S, Fisher J, Sessler DI: Hypercapnia 
improves tissue oxygenation. Anesthesiology 2002, 97:801-806.
31.  Akca O, Sessler DI, Delong D, Keijner R, Ganzel B, Doufas AG: Tissue 
oxygenation response to mild hypercapnia during cardiopulmonary 
bypass with constant pump output. Br J Anaesth 2006, 96:708-714.
32.  Wang Z, Su F, Bruhn A, Yang X, Vincent JL: Acute hypercapnia improves 
indices of tissue oxygenation more than dobutamine in septic shock. Am J 
Respir Crit Care Med 2008, 177:178-183.
This article is part of a review series on Gaseous mediators, edited by 
Peter Radermacher. Other articles in the series can be found online at 
http://ccforum.com/series/gaseous_mediators
Curley et al. Critical Care 2010, 14:220 
http://ccforum.com/content/14/2/220
Page 6 of 733.  Komori M, Takada K, Tomizawa Y, Nishiyama K, Kawamata M, Ozaki M: 
Permissive range of hypercapnia for improved peripheral microcirculation 
and cardiac output in rabbits. Crit Care Med 2007, 35:2171-2175.
34.  Hillered L, Ernster L, Siesjo BK: Infl  uence of in vitro lactic acidosis and 
hypercapnia on respiratory activity of isolated rat brain mitochondria. 
J Cereb Blood Flow Metab 1984, 4:430-437.
35.  Sinclair SE, Kregenow DA, Lamm WJ, Starr IR, Chi EY, Hlastala MP: Hypercapnic 
acidosis is protective in an in vivo model of ventilator-induced lung injury. 
Am J Respir Crit Care Med 2002, 166:403-408.
36. Laff  ey JG, Engelberts D, Duggan M, Veldhuizen R, Lewis JF, Kavanagh BP: 
Carbon dioxide attenuates pulmonary impairment resulting from 
hyperventilation. Crit Care Med 2003, 31:2634-2640.
37.  Rai S, Engelberts D, Laff  ey JG, Frevert C, Kajikawa O, Martin TR, Post M, 
Kavanagh BP: Therapeutic hypercapnia is not protective in the in vivo 
surfactant-depleted rabbit lung. Pediatr Res 2004, 55:42-49.
38.  Ooi H, Cadogan E, Sweeney M, Howell K, O’Regan RG, McLoughlin P: Chronic 
hypercapnia inhibits hypoxic pulmonary vascular remodeling. Am J Physiol 
Heart Circ Physiol 2000, 278:H331-H338.
39.  Kantores C, McNamara PJ, Teixeira L, Engelberts D, Murthy P, Kavanagh BP, 
Jankov RP: Therapeutic hypercapnia prevents chronic hypoxia-induced 
pulmonary hypertension in the newborn rat. Am J Physiol Lung Cell Mol 
Physiol 2006, 291:L912-L922.
40.  Masood A, Yi M, Lau M, Belcastro R, Shek S, Pan J, Kantores C, McNamara PJ, 
Kavanagh BP, Belik J, Jankov RP, Tanswell AK: Therapeutic eff  ects of 
hypercapnia on chronic lung injury and vascular remodeling in neonatal 
rats. Am J Physiol Lung Cell Mol Physiol 2009, 297:L920-L930.
41.  Ni Chonghaile M, Higgins BD, Costello JF, Laff  ey JG: Hypercapnic acidosis 
attenuates severe acute bacterial pneumonia-induced lung injury by a 
neutrophil-independent mechanism. Crit Care Med 2008, 36:3135-3144.
42.  Ni Chonghaile M, Higgins BD, Costello J, Laff  ey JG: Hypercapnic acidosis 
attenuates lung injury induced by established bacterial pneumonia. 
Anesthesiology 2008, 109:837-848.
43.  O’Croinin DF, Nichol AD, Hopkins N, Boylan J, O’Brien S, O’Connor C, Laff  ey JG, 
McLoughlin P: Sustained hypercapnic acidosis during pulmonary infection 
increases bacterial load and worsens lung injury. Crit Care Med 2008, 
36:2128-2135.
44.  Costello J, Higgins B, Contreras M, Chonghaile MN, Hassett P, O’Toole D, Laff  ey 
JG: Hypercapnic acidosis attenuates shock and lung injury in early and 
prolonged systemic sepsis. Crit Care Med 2009, 37:2412-2420.
45.  Higgins BD, Costello J, Contreras M, Hassett P, D OT, Laff  ey JG: Diff  erential 
eff  ects of buff  ered hypercapnia versus hypercapnic acidosis on shock and 
lung injury induced by systemic sepsis. Anesthesiology 2009, 111:1317-1326.
46.  Briva A, Vadasz I, Lecuona E, Welch LC, Chen J, Dada LA, Trejo HE, Dumasius V, 
Azzam ZS, Myrianthefs PM, Batlle D, Gruenbaum Y, Sznajder JI: High CO2 
levels impair alveolar epithelial function independently of pH. PLoS One 
2007, 2:e1238.
47.  Myrianthefs PM, Briva A, Lecuona E, Dumasius V, Rutschman DH, Ridge KM, 
Baltopoulos GJ, Sznajder JI: Hypocapnic but not metabolic alkalosis impairs 
alveolar fl  uid reabsorption. Am J Respir Crit Care Med 2005, 171:1267-1271.
48.  Edmunds LH, Jr, Holm JC: Eff  ect of inhaled CO2 on hemorrhagic 
consolidation due to unilateral pulmonary arterial ligation. J Appl Physiol 
1969, 26:710-715.
49. Laff  ey JG, Engelberts D, Kavanagh BP: Injurious eff  ects of hypocapnic 
alkalosis in the isolated lung. Am J Respir Crit Care Med 2000, 
162(2 Pt 1):399-405.
50.  Kitakaze M, Takashima S, Funaya H, Minamino T, Node K, Shinozaki Y, Mori H, 
Hori M: Temporary acidosis during reperfusion limits myocardial infarct 
size in dogs. Am J Physiol 1997, 272(5 Pt 2):H2071-H2078.
51.  Nomura F, Aoki M, Forbess JM, Mayer JE, Jr: Eff  ects of hypercarbic acidotic 
reperfusion on recovery of myocardial function after cardioplegic 
ischemia in neonatal lambs. Circulation 1994, 90(5 Pt 2):II321-II327.
52.  Vannucci RC, Towfi  ghi J, Heitjan DF, Brucklacher RM: Carbon dioxide protects 
the perinatal brain from hypoxic-ischemic damage: an experimental study 
in the immature rat. Pediatrics 1995, 95:868-874.
53.  Safar P, Xiao F, Radovsky A, Tanigawa K, Ebmeyer U, Bircher N, Alexander H, 
Stezoski SW: Improved cerebral resuscitation from cardiac arrest in dogs 
with mild hypothermia plus blood fl  ow promotion. Stroke 1996, 
27:105-113.
54.  Huttunen J, Tolvanen H, Heinonen E, Voipio J, Wikstrom H, Ilmoniemi RJ, Hari 
R, Kaila K: Eff  ects of voluntary hyperventilation on cortical sensory 
responses. Electroencephalographic and magnetoencephalographic 
studies. Exp Brain Res 1999, 125:248-254.
55.  Pastuszko P, Wilson DF: Activation of tyrosine hydroxylase in striatum of 
newborn piglets in response to hypocapnic ischemia and recovery. Adv 
Exp Med Biol 1997, 411:65-73.
56.  Mykita S, Golly F, Dreyfus H, Freysz L, Massarelli R: Eff  ect of CDP-choline on 
hypocapnic neurons in culture. J Neurochem 1986, 47:223-231.
57. Laff  ey JG, Kavanagh BP: Hypocapnia. N Engl J Med 2002, 347:43-53.
58.  Trimble C, Smith DE, Rosenthal MH, Fosburg RG: Pathophysiologic role of 
hypocarbia in post-traumatic pulmonary insuffi   ciency. Am J Surg 1971, 
122:633-638.
59.  Muizelaar JP, Marmarou A, Ward JD, Kontos HA, Choi SC, Becker DP, Gruemer 
H, Young HF: Adverse eff  ects of prolonged hyperventilation in patients 
with severe head injury: a randomized clinical trial. J Neurosurg 1991, 
75:731-739.
60.  Buunk G, van der Hoeven JG, Meinders AE: Cerebrovascular reactivity in 
comatose patients resuscitated from a cardiac arrest. Stroke 1997, 
28:1569-1573.
61.  Yokoyama I, Inoue Y, Kinoshita T, Itoh H, Kanno I, Iida H: Heart and brain 
circulation and CO2 in healthy men. Acta Physiol (Oxf) 2008, 193:303-308.
62.  Hirano Y, Ozasa Y, Yamamoto T, Uehara H, Yamada S, Nakagawa K, Ikawa H, 
Ishikawa K: Hyperventilation and cold-pressor stress echocardiography for 
noninvasive diagnosis of coronary artery spasm. J Am Soc Echocardiogr 
2001, 14:626-633.
63.  du Plessis AJ, Jonas RA, Wypij D, Hickey PR, Riviello J, Wessel DL, Roth SJ, 
Burrows FA, Walter G, Farrell DM, Walsh AZ, Plumb CA, del Nido P, Burke RP, 
Castaneda AR, Mayer JE, Jr, Newburger JW: Perioperative eff  ects of alpha-
stat versus pH-stat strategies for deep hypothermic cardiopulmonary 
bypass in infants. J Thorac Cardiovasc Surg 1997, 114:991-1000; discussion 
1000-1001.
64.  Mekontso Dessap A, Charron C, Devaquet J, Aboab J, Jardin F, Brochard L, 
Vieillard-Baron A: Impact of acute hypercapnia and augmented positive 
end-expiratory pressure on right ventricle function in severe acute 
respiratory distress syndrome. Intensive Care Med 2009, 35:1850-1858.
65.  Li J, Hoskote A, Hickey C, Stephens D, Bohn D, Holtby H, Van Arsdell G, 
Redington AN, Adatia I: Eff  ect of carbon dioxide on systemic oxygenation, 
oxygen consumption, and blood lactate levels after bidirectional superior 
cavopulmonary anastomosis. Crit Care Med 2005, 33:984-989.
66. Laff  ey JG, Engelberts D, Kavanagh BP: Buff  ering hypercapnic acidosis 
worsens acute lung injury. Am J Respir Crit Care Med 2000, 161:141-146.
67.  Nichol AD, O’Cronin DF, Howell K, Naughton F, O’Brien S, Boylan J, O’Connor 
C, O’Toole D, Laff  ey JG, McLoughlin P: Infection-induced lung injury is 
worsened after renal buff  ering of hypercapnic acidosis. Crit Care Med 2009, 
37:2953-2961.
68.  Nahas GG, Sutin KM, Fermon C, Streat S, Wiklund L, Wahlander S, Yellin P, 
Brasch H, Kanchuger M, Capan L, Manne J, Helwig H, Gaab M, Pfenninger E, 
Wetterberg T, Holmdahl M, Turndorf H: Guidelines for the treatment of 
acidaemia with THAM. Drugs 1998, 55:191-224.
doi:10.1186/cc8926
Cite this article as: Curley G, et al.: Bench-to-bedside review: Carbon 
dioxide. Critical Care 2010, 14:220.
Curley et al. Critical Care 2010, 14:220 
http://ccforum.com/content/14/2/220
Page 7 of 7